GeneDx Holdings Corp (WGS)

Currency in USD
81.74
+3.86(+4.96%)
Closed·
80.11-1.63(-1.99%)
·
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
75.7083.37
52 wk Range
32.21170.87
Key Statistics
Prev. Close
77.88
Open
76.95
Day's Range
75.7-83.37
52 wk Range
32.21-170.87
Volume
646.78K
Average Volume (3m)
1.04M
1-Year Change
-26.0539%
Book Value / Share
8.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WGS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.89
Upside
+5.08%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

GeneDx Holdings Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 85.89
(+5.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy90.00+10.11%75.00Maintain04/08/2026
Guggenheim
Buy74.00-9.47%70.00Maintain29/06/2026
Piper Sandler
Buy63.00-22.93%50.00Maintain23/06/2026
Craig-Hallum
Buy85.00+3.99%153.00Maintain05/05/2026
Wells Fargo
Buy75.00-8.25%155.00Maintain05/05/2026

GeneDx Holdings Corp Earnings Call Summary for Q2/2026

  • GeneDx Q2 revenue hit $114.4M, beating forecasts by 3.05%; achieved adjusted net income of $0.4M one quarter ahead of plan despite EPS miss of $0.28.
  • Exome and genome test volume surged 32% YoY to record 30,785 tests; gross margin improved to 70% after completing $25M in annual cost reductions.
  • Shares jumped 15.1% to $75 in after-hours trading on strong volume growth and earlier-than-expected profitability milestone.
  • Company reaffirmed 2026 guidance of $475M-$490M revenue with 30%+ volume growth; Q3 revenue expected at $122M-$124M with ~$2M adjusted net income.
  • Management prioritizes revenue cycle improvements to boost collection rates toward 70% industry standard, with biggest gains expected in 2027 from payer coverage.
Last Updated: 04/08/2026, 07:40 am
Read Full Transcript

Earnings

Latest Release
03/08/2026
EPS / Forecast
-0.28 / -0.14
Revenue / Forecast
114.4M / 111.01M
EPS Revisions
Last 90 days

WGS Income Statement

Compare WGS to Peers and Sector

Metrics to compare
WGS
Peers
Sector
Relationship
P/E Ratio
−23.2x−44.1x−0.4x
PEG Ratio
0.000.520.00
Price/Book
10.1x2.9x2.6x
Price / LTM Sales
5.4x1.6x3.1x
Upside (Analyst Target)
15.6%19.7%48.2%
Fair Value Upside
Unlock−5.5%5.8%Unlock

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.47M35.12%815.79M
Other Institutional Investors
32.18M64.88%2.51B
Public Companies & Retail Investors
0.000.00%0.00
Total
42.65M100.00%3.32B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Corvex Management LP16.04%4,784,570372,622
Casdin Capital, LLC12.50%3,726,411290,213

People Also Watch

10.34
XNDU
-1.99%
5.750
SATL
+7.88%
4.350
RXT
-8.03%
10.655
RCAT
+6.55%
9.4000
ASTC
-3.59%

FAQ

What Is the GeneDx Holdings (WGS) Stock Price Today?

The GeneDx Holdings stock price today is 81.74 USD.

What Stock Exchange Does GeneDx Holdings Trade On?

GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for GeneDx Holdings?

The stock symbol for GeneDx Holdings is "WGS."

What Is the GeneDx Holdings Market Cap?

As of today, GeneDx Holdings market cap is 2.45B USD.

What Is GeneDx Holdings's Earnings Per Share (TTM)?

The GeneDx Holdings EPS (TTM) is -3.64.

When Is the Next GeneDx Holdings Earnings Date?

GeneDx Holdings will release its next earnings report on 03/11/2026.

From a Technical Analysis Perspective, Is WGS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has GeneDx Holdings Stock Split?

GeneDx Holdings has split 1 times.

How Many Employees Does GeneDx Holdings Have?

GeneDx Holdings has 1300 employees.

What is the current trading status of GeneDx Holdings (WGS)?

As of 11/08/2026, GeneDx Holdings (WGS) is trading at a price of 81.74 USD, with a previous close of 77.88 USD. The stock has fluctuated within a day range of 75.70 USD to 83.37 USD, while its 52-week range spans from 32.21 USD to 170.87 USD.

What Is GeneDx Holdings (WGS) Price Target According to Analysts?

The average 12-month price target for GeneDx Holdings is 85.89 USD, with a high estimate of 103 USD and a low estimate of 63 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +5.08% Upside potential.

What Is the WGS Premarket Price?

WGS's last pre-market stock price is 76.20 USD. The pre-market share volume is 510.00, and the stock has decreased by -1.68, or -2.16%.

What Is the WGS After Hours Price?

WGS's last after hours stock price is 80.11 USD, the stock has decreased by -1.63, or -1.99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.